Nostos Genomics has raised $5.7 million in a recent funding round, securing investment capital from investors. The company partners with genetic testing labs to transform complex data into actionable genomic insights, aiming to provide faster and clearer diagnoses for individuals living with genetic diseases. This investment will support Nostos Genomics in its mission to address the significant challenges in diagnosing rare genetic conditions.
Currently, over 300 million people worldwide are affected by rare genetic diseases, often enduring diagnostic journeys that span more than five years, frequently resulting in incorrect or absent diagnoses. While new technologies have expanded access to genetic testing, the critical step of interpreting mutations remains a laborious and costly bottleneck for labs. This process can take weeks for a single patient, and limited understanding of mutation consequences often leaves 70% of patients without a definitive diagnosis.
Nostos Genomics addresses this challenge with its CE-certified platform, which leverages a unique combination of machine learning and synthetic biology. This technology characterizes mutations at scale and automates the interpretation process, enabling genetic testing labs to diagnose more people in a fraction of the time. The $5.7 million in capital will be strategically deployed to accelerate the company's growth initiatives, scale its operational capabilities, and further enhance its platform's reach and functionality.
This funding round marks a significant step for Nostos Genomics as it continues to advance its technology and expand its partnerships with genetic testing labs. The company plans to use the funds to strengthen its market position and ultimately improve diagnostic outcomes for millions of individuals awaiting a clear understanding of their genetic conditions.
